

Citations

1. McIntyre M. Commentary: time to research echinacea properly. *J Altern Complement Med* 2005;11:1027-1029.
2. Linde K, Barrett B, Wolkart K et al. Echinacea for preventing and treating the common cold. *Cochrane Database Syst Rev* 2006;CD000530.
3. Raduner S, Majewska A, Chen JZ et al. Alkylamides from Echinacea are a new class of cannabinomimetics: CB2-receptor dependent and independent immunomodulatory effects. *J Biol Chem* 2006;281:1192-206.
4. Pugh ND, Balachandran P, Lata H et al. Melanin: dietary mucosal immune modulator from Echinacea and other botanical supplements. *Int Immunopharmacol* 2005;5:637-647.
5. Felter H, Lloyd J. Echinacea. King's American Dispensatory. 1 vol. 1898, Reprint ed. Sandy, Ore: Eclectic Medical Publications; 1983:671-677.
6. Felter H. The Eclectic Materia Medica, Pharmacology and Therapeutics. Portland, Ore: Eclectic Medical Publications; 1985 ed. Cincinnati, Ohio; 1922.
7. Brinker F. Complex Herbs: Complete Medicines: a Merger of Eclectic and Naturopathic Visions of Botanical Medicine. Sandy, Ore: Eclectic Medical Publications; 2004.
8. Mills S, Bone K. Principles and Practice of Phytotherapy. Edinburgh: Churchill Livingstone; 2000.
9. Wichtl M. Echinaceae herba/radix. In: Bisset N, ed. Wichtl's Herbal Drugs and Phytopharmaceuticals. 2nd ed. Stuttgart: Medpharm GmbH; 1994:182-184.
10. WHO. Herba Echinaceae Purpureae. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:136-144.
11. WHO. Radix Echinaceae. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:125-135.
12. Bradley P. British Herbal Compendium. 1 vol. Bournemouth, UK: British Herbal Medical Association; 1992.
13. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998:685.
14. Upton R. Echinacea purpurea root. American Herbal Pharmacopoeia. Scotts Valley, Calif; 2004.
15. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. *Oncology (Huntingt)* 2001;15:1267-1272; discussion 1272-1268, 1283.
16. Mills S, Bone K. Echinacea. Principles and Practice of Phytotherapy. Edinburgh: Churchill Livingstone; 2000:354-361.
17. Mitchell W. Echinacea angustifolia. In: Plant Medicine in Practice. St Louis: Churchill Livingstone; 2003:52.
18. Coeugnet E, Kuhnast R. Adjuvant immunotherapy with different formulations of Echinacin. *Therapiewoche* 1986;36:3352-3358.
19. Miller SC. Echinacea: a miracle herb against aging and cancer? Evidence in vivo in mice. *Evid Based Complement Altern Med* 2005;2:309-314.
20. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. *Integr Cancer Ther* 2003;2:247-267.
21. Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine* 2000;7:273-282.
22. Matthias A, Blanchfield JT, Penman KG et al. Permeability studies of alkylamides and caffeic acid conjugates from echinacea using a Caco-2 cell monolayer model. *J Clin Pharm Ther* 2004;29:7-13.
23. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. *J Altern Complement Med* 2005;11:433-439.
24. Fuchikami H, Satoh H, Tsujimoto M et al. Effects of herbal extracts on the function of human organic anion transporting polypeptide, OATP-B. *Drug Metab Dispos* 2006;34:577-582.
25. Gorski JC, Huang S-M, Pinto A et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther* 2004;75:89-100.
26. Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. *Econ Med Plant Res* 1991;5:253-321.
27. Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML. Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea. *Infect Immun* 1984;46:845-849.
28. Luettig B, Steinmuller C, Gifford GE et al. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. *J Natl Cancer Inst* 1989;81:669-675.
29. Roesler J, Emmendorffer A, Steinmuller C et al. Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to test subjects mediates activation of the phagocyte system. *Int J Immunopharmacol* 1991;13:931-941.
30. Goel V, Chang C, Slama J et al. Echinacea stimulates macrophage function in the lung and spleen of normal rats. *J Nutr Biochem* 2002;13:487.

Citations and Reference Literature: Echinacea

31. Gan XH, Zhang L, Heber D, Bonavida B. Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. *Int Immunopharmacol* 2003;3:811-824.
32. Steinmuller C, Roesler J, Grottrup E et al. Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with *Candida albicans* and *Listeria monocytogenes*. *Int J Immunopharmacol* 1993;15:605-614.
33. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. *Immunopharmacology* 1997;35:229-235.
34. Matar P, Rozados VR, Gonzalez AD et al. Mechanism of antimetastatic immunopotentiality by low-dose cyclophosphamide. *Eur J Cancer* 2000;36:1060-1066.
35. Berd D, Mastrangelo MJ, Engstrom PF et al. Augmentation of the human immune response by cyclophosphamide. *Cancer Res* 1982;42:4862-4866.
36. Mihich E, Ehrke MJ. Anticancer drugs plus cytokines: immunomodulation based therapies of mouse tumors. *Int J Immunopharmacol* 2000;22:1077-1081.
37. Ishiyama N, Utsuyama M, Kitagawa M, Hirokawa K. Immunological enhancement with a low dose of cyclophosphamide in aged mice. *Mech Ageing Dev* 1999;111:1-12.
38. Burger RA, Torres AR, Warren RP et al. Echinacea-induced cytokine production by human macrophages. *Int J Immunopharmacol* 1997;19:371-379.
39. Lersch C, Zeuner M, Bauer A et al. Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), thymostimulin, and Echinacea purpurea extracts (Echinacin) in patients with far advanced colorectal cancers: preliminary results. *Cancer Invest* 1992;10:343-348.
40. Lersch C, Zeuner M, Bauer A et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), Echinacea purpurea extracts (Echinacin) and thymostimulin. *Arch Geschwulstforsch* 1990;60:379-383.
41. Bodinet C, Lindequist U, Teuscher E, Freudenstein J. Effect of an orally applied herbal immunomodulator on cytokine induction and antibody response in normal and immunosuppressed mice. *Phytomedicine* 2002;9:606-613.
42. Randolph RK, Gellenbeck K, Stonebrook K et al. Regulation of human immune gene expression as influenced by a commercial blended Echinacea product: preliminary studies. *Exp Biol Med* (Maywood) 2003;228:1051-1056.
43. Currier NL, Miller SC. Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated. *Exp Gerontol* 2000;35:627-639.
44. Currier NL, Sicotte M, Miller SC. Deleterious effects of Echinacea purpurea and melatonin on myeloid cells in mouse spleen and bone marrow. *J Leukoc Biol* 2001;70:274-276.
45. Mustea I, Postescu ID, Tamas M, Rasnita TD. Experimental evaluation of protective activity of Echinacea pallida against cisplatin toxicity. *Phytother Res* 1997;11:263-265.
46. Bendel R, Bendel V, Renner K et al. [Additional treatment with Esberitox N in patients with chemo-radiotherapy treatment of advanced breast cancer]. *Onkologie* 1989;12 Suppl 3:32-38.
47. Melchart D, Clemm C, Weber B et al. Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy: a pilot study. *Phytother Res* 2002;16:138-142.
48. Coeugniet EG, Elek E. Immunomodulation with *Viscum album* and Echinacea purpurea extracts. *Onkologie* 1987;10:27-33.
49. Elsasser-Beile U, Willenbacher W, Bartsch HH et al. Cytokine production in leukocyte cultures during therapy with Echinacea extract. *J Clin Lab Anal* 1996;10:441-445.
50. Schwarz E, Metzler J, Diedrich JP et al. Oral administration of freshly expressed juice of Echinacea purpurea herbs fail to stimulate the nonspecific immune response in healthy young men: results of a double-blind, placebo-controlled crossover study. *J Immunother* 2002;25:413-420.
51. Calabrese LH. Molecular differences in anticytokine therapies. *Clin Exp Rheumatol* 2003;21:241-248.
52. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. *Rheum Dis Clin North Am* 2003;29:185-202.
53. Taylor JA, Weber W, Standish L et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. *JAMA* 2003;290:2824-2830.
54. Kim L, Wollner D, Anderson P, Brammer D. Echinacea for treating colds in children. *JAMA* 2004;291:1323; author reply 1324.
55. Firenzuoli F, Gori L. Echinacea for treating colds in children. *JAMA* 2004;291:1323-1324; author reply 1324.
56. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med* 1998;158:2200-2211.

Citations and Reference Literature: Echinacea

57. Roder E, Wiedenfeld H, Hille T, Britz-Kirstgen R. Pyrrolizidine alkaloids in *Echinacea angustifolia* and *E. purpurea*. *Dtsch Apoth Ztg* 1984;124:2316-2318.
58. Bone K. Echinacea: when should it be used? *Mod Phytotherapist* 1997;3:17-21.
59. McLeod D. Case history of chronic lymphocytic leukemia. *Mod Phytotherapist* 1996;2:34-35.
60. Berman S, Justis J, Tiles J, Ma C. Dramatic increase in immune mediated HIV killing activity induced by *Echinacea angustifolia* [abstract No 32309]. *International Conference on AIDS* 1998;12:582.
61. Parnham M. Benefit-risk assessment of the squeezed sap of the purple coneflower (*Echinacea purpurea*) for long term oral immunostimulation. *Phytomedicine* 1996;3:95-102.
62. Mullins RJ. Echinacea-associated anaphylaxis. *Med J Aust* 1998;168:170-171.
63. Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. *Ann Allergy Asthma Immunol* 2002;88:42-51.
64. Bruynzeel DP, van Ketel WG, Young E et al. Contact sensitization by alternative topical medicaments containing plant extracts. The Dutch Contact Dermatoses Group. *Contact Dermatitis* 1992;27:278-279.
65. Hill LL, Foote JC, Erickson BD et al. *Echinacea purpurea* supplementation stimulates select groups of human gastrointestinal tract microbiota. *J Clin Pharm Ther* 2006;31:599-604.